Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on the Copenhagen...

Area of Science:

• Oncology
• Hematology
• Epidemiology

Background:

• Eosinophilia can be an early indicator of malignancy and a host anti-tumor response.
• The link between eosinophilia and solid tumor development has not been previously studied in an epidemiological context.
• This study aimed to explore eosinophilia as a potential biomarker for solid tumor development.

Purpose of the Study:

• To investigate the association between eosinophilia in routine blood samples and the subsequent development of solid tumors.
• To determine if eosinophilia serves as a predictive biomarker for cancer risk.
• To examine the relationship between different levels of eosinophilia and cancer incidence.

Main Methods:

• Utilized the Copenhagen Primary Care Differential Count (CopDiff) Database (2000-2007) with 356,196 individuals.
• Categorized eosinophil counts into no, mild, and severe levels.
• Linked data with Danish registries to track solid tumors and all-cause mortality within three years post-blood count, using multivariable logistic regression.

Main Results:

• A statistically significant increased risk of bladder cancer was observed in individuals with mild eosinophilia (OR 1.93, p=0.0013).
• No significant associations were found between eosinophilia and other solid cancers.
• The findings suggest a specific link between mild eosinophilia and bladder cancer risk.

Conclusions:

• Eosinophilia in routine blood tests is associated with an elevated risk of bladder cancer.
• Further preclinical research is necessary to elucidate the role of eosinophils in carcinogenesis.
• It remains undetermined whether eosinophils promote tumor immune surveillance or contribute to neoplastic progression.